Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplant. 2021.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel (tisa-cel) Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023.
Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant Cell Ther. 2021.
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analys. Clin Lymphoma Myeloma Leuk. 2023.
Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients. Transplant Cell Ther. 2021.
Impact of COVID-19 in Hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis. 2022.
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023..
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. Transplant Cell Ther. 2023.